MedTrace Logo

PET Imaging With 89Zr-DFO-Trastuzumab in Esophagogastric Cancer

NCT02023996 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 42

Last updated 2024-12-10

Study results available
· View outcomes & findings →

Summary

The purpose of the first group (Group 1) was to find the optimal time for taking pictures after injection of 89Zr-DFO-trastuzumab, to see how long it stayed in the blood, and to see how well it was tolerated. From what the investigators have learned from Group 1, patients in Group 2 no longer need serial scans or serial blood draws. This study is based on a cohort expansion. All data is appropriately reported as there is only one study cohort

Conditions

  • Esophagogastric Cancer

Interventions

RADIATION

89Zr-DFO-trastuzumab

DEVICE

PET imaging

Sponsors & Collaborators

Principal Investigators

  • Neeta Pandit-Taskar, MD · Memorial Sloan Kettering Cancer Center

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-12-31
Primary Completion
2023-06-27
Completion
2023-06-27

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02023996 on ClinicalTrials.gov